ISSUE 1523
| The full issue is available to subscribers | Subscriber Login |
The FDA has approved abaloparatide (Tymlos – Radius Health), a synthetic analog of human parathyroid hormone related peptide, for treatment of postmenopausal women with osteoporosis who are at high risk for fracture. Abaloparatide is the second parathyroid hormone receptor agonist to be approved for this indication; teriparatide (Forteo – Lilly), a recombinant parathyroid hormone analog, was the first. They are the only drugs approved for treatment of osteoporosis that stimulate bone formation. Other drugs used for this indication inhibit bone resorption.1
ACTIVITY — Given continuously, human parathyroid hormone has a catabolic effect on bone, but when it is given once daily in low doses, bone formation predominates. Abaloparatide, like teriparatide, increases bone mineral density (BMD) and bone formation markers.Would you like to read the rest of this issue? Gain access below.
